NeuroSense Therapeutics (NASDAQ:NRSN) CFO Or Eisenberg Purchases 250,000 Shares of Stock

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) CFO Or Eisenberg acquired 250,000 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was purchased at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the transaction, the chief financial officer directly owned 1,504,050 shares in the company, valued at approximately $1,203,240. The trade was a 19.94% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

NeuroSense Therapeutics Stock Performance

NASDAQ NRSN opened at $0.71 on Thursday. The stock has a market capitalization of $22.95 million, a P/E ratio of -1.31 and a beta of 1.56. NeuroSense Therapeutics Ltd. has a 52 week low of $0.63 and a 52 week high of $2.52. The stock has a fifty day moving average of $0.78 and a 200-day moving average of $0.86.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of NeuroSense Therapeutics in the second quarter valued at approximately $54,000. Squarepoint Ops LLC boosted its holdings in NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares during the last quarter. Two Sigma Investments LP bought a new position in NeuroSense Therapeutics in the third quarter valued at $26,000. Finally, Yorkville Advisors Global LP acquired a new stake in NeuroSense Therapeutics in the 4th quarter valued at $77,000. 1.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on NRSN shares. Roth Mkm initiated coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They set a “buy” rating and a $3.00 price objective for the company. D. Boral Capital reiterated a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.